Methamphetamine (Meth) is a new recreational drug. Based on the USA Food and Drug Administration, approximately 38 million people are reported as having an addiction to Meth and/or its related derivatives. Unexpectedly, Meth is the most commonly used substance after Cannabis (
1). It is known as the sympathomimetic drug that has been reported to cause several physical and psychological side effects such as un Normal able repetitive movements, sweating, pupil dilation, and severe behavioral reactions (
2). It also causes behavioral consequences including sensitization, Meth discriminative stimulus effects, and hyper motor activity by inducing neuroinflammation. Based on several studies, behavioral effects may be caused by the role of Meth in regulating the level of 3′-5′-cyclic adenosine monophosphate (cAMP). It could be responsible for the behavioral effects of Meth such as hyper motor activity. Meth has also a role in mediating inhibition of phosphodiesterase (PDE), the enzyme that is responsible for cAMP degradation (
3). Meth severely damages different regions of the brain (
4). Its chronic use may lead to neurodegeneration of cortex, hippocampus and midbrain areas (
5). Severe symptoms of Meth abuse can be due to hippocampal-dependent memory changes (
6). Several experimental studies have demonstrated that astrocytes and microglia are stimulated in rodents which were treated by a toxic Meth regime (
7-
9). Meth exposure is associated with microglial activation and along with that, it induces secretion of proinflammatory cytokines and ultimately causes drug induced-behavioral changes which could be attenuated by modulation of activated glial cells (
10). Previous studies have revealed astrocyte activation in Meth-induced toxicity (
11,
12). Some researchers showed Meth-induced toxicity was related to dramatic elevation in the levels of GFAP which was more prominent in the striatum and interestingly this sub-region is more vulnerable to the toxic effects of Meth. The loss of dopamine-transporter binding sites and the immune reactivity of tyrosine-hydroxylase are the most in the striatum (
13). Based on astrogliosis analysis among Meth-treated animals, it is evident that the astroglial response reaches its peak within 2 days after administration and remains high for at least 7 days (
14). Furthermore, a correlation was observed between the Meth-induced activation of astrocytes and toxicity (
15). In fact, after Meth treatment, astrocyte can actively respond in a short period of time and this response can be relatively prolonged. Since astrocytes have phenotypic changes capability and dynamic response potential, they can play an important role in the neuropathological consequences of CNS injuries (
16). The Meth-induced microglial responses, for instance, expresses calcium binding adaptor protein (Iba-1) that may be responsible for the neuropathological alterations secondary to neurotoxic effects of Meth (
17). Extensive research evidence indicates that attenuation of microglial activation can decrease Meth- induced behavioral changes (18-20). For instance, Ibudilast (3-isobutyryl-2-isopropylpyrazolo [1,5- a] pyridine) is a non-selective PDE inhibitor and anti-inflammatory glial cell modulator that can attenuate Meth-induced locomotor activity and its sensitization in mice (
21). As well, treatment with minocycline hydrochloride (other anti-inflammatory drugs) significantly reduces microglial activation caused by Meth and attenuates Meth-induced behavioral deficits (
22,
23). The purpose of this study is to explore whether chronic Meth use can induce GFAP and Iba-1 upregulation and neuronal apoptosis in the CA1 region of the postmortem hippocampus.